[HTML][HTML] Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
Objective Oral tyrosine kinase inhibitor has been shown to prolong progression-free survival
(PFS) in epidermal growthfactor receptor (EGFR) mutation positive adenocarcinoma; …
(PFS) in epidermal growthfactor receptor (EGFR) mutation positive adenocarcinoma; …
[HTML][HTML] Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
VM Patil, V Noronha, A Joshi, AB Choughule… - ESMO Open, 2017 - esmoopen.com
Objective Oral tyrosine kinase inhibitor has been shown to prolong progression-free survival
(PFS) in epidermal growthfactor receptor (EGFR) mutation positive adenocarcinoma; …
(PFS) in epidermal growthfactor receptor (EGFR) mutation positive adenocarcinoma; …
Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma.
VM Patil, V Noronha, A Joshi, AB Choughule… - ESMO Open, 2017 - europepmc.org
Objective Oral tyrosine kinase inhibitor has been shown to prolong progression-free survival
(PFS) in estimated glomerular filtration rate (EGFR) mutation positive adenocarcinoma; …
(PFS) in estimated glomerular filtration rate (EGFR) mutation positive adenocarcinoma; …
[引用][C] Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
VM Patil, V Noronha, A Joshi, AB Choughule… - ESMO Open, 2017 - cir.nii.ac.jp
Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung
adenocarcinoma | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
adenocarcinoma | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
[PDF][PDF] Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
VM Patil, V Noronha, A Joshi, AB Choughule… - academia.edu
Objective Oral tyrosine kinase inhibitor has been shown to prolong progression-free survival
(PFS) in epidermal growthfactor receptor (EGFR) mutation positive adenocarcinoma; …
(PFS) in epidermal growthfactor receptor (EGFR) mutation positive adenocarcinoma; …
[HTML][HTML] Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
VM Patil, V Noronha, A Joshi, AB Choughule… - ESMO Open, 2017 - ncbi.nlm.nih.gov
Objective Oral tyrosine kinase inhibitor has been shown to prolong progression-free survival
(PFS) in epidermal growthfactor receptor (EGFR) mutation positive adenocarcinoma; …
(PFS) in epidermal growthfactor receptor (EGFR) mutation positive adenocarcinoma; …
Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
VM Patil, V Noronha, A Joshi, AB Choughule… - ESMO …, 2017 - pubmed.ncbi.nlm.nih.gov
Objective Oral tyrosine kinase inhibitor has been shown to prolong progression-free survival
(PFS) in estimated glomerular filtration rate (EGFR) mutation positive adenocarcinoma; …
(PFS) in estimated glomerular filtration rate (EGFR) mutation positive adenocarcinoma; …
Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma.
VM Patil, V Noronha, A Joshi, AB Choughule… - ESMO Open, 2017 - europepmc.org
Objective Oral tyrosine kinase inhibitor has been shown to prolong progression-free survival
(PFS) in estimated glomerular filtration rate (EGFR) mutation positive adenocarcinoma; …
(PFS) in estimated glomerular filtration rate (EGFR) mutation positive adenocarcinoma; …
[PDF][PDF] Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
VM Patil, V Noronha, A Joshi, AB Choughule… - academia.edu
Objective Oral tyrosine kinase inhibitor has been shown to prolong progression-free survival
(PFS) in epidermal growthfactor receptor (EGFR) mutation positive adenocarcinoma; …
(PFS) in epidermal growthfactor receptor (EGFR) mutation positive adenocarcinoma; …